Padua Prediction Score for VTE Risk
Estimates VTE risk in hospitalised medical patients to guide thromboprophylaxis decisions.
Score interpretation
Padua < 4: Low risk (~0.3% VTE rate). Pharmacological prophylaxis not routinely required.
→ Mechanical prophylaxis (TED stockings, pneumatic compression). Encourage early mobilisation. Reassess daily.
Padua ≥ 4: High risk (~11% VTE rate). Pharmacological prophylaxis indicated.
→ Start LMWH (adults: enoxaparin 40mg SC OD) unless contraindicated. Adjust dose in renal impairment. Assess bleeding risk (IMPROVE Bleeding Score). Children: use a children's formulary.
Interpretation bands for the Padua Score. Apply clinical judgement and local guidance.
References
- Barbar S, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8(11):2450–2457.
Related
Curated clinical cross-links plus same-class fallbacks.
- Enoxaparin (LMWH) · Anticoagulant
- Enoxaparin · Low Molecular Weight Heparin (LMWH)
- Enoxaparin sodium · Low molecular weight heparin (LMWH)
- Dalteparin sodium · Low molecular weight heparin (LMWH)
- Bemiparin sodium · Low molecular weight heparin (LMWH)
- Enoxaparin (VTE in Pregnancy) · Low Molecular Weight Heparin (LMWH) — VTE Prophylaxis/Treatment
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.